Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is developing technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient. The technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile. The R&D is taking place in collaboration with the University Hospital Basel’s Liechti Lab, the leading research center focused on the pharmacology of psychedelic substances.
A considerable problem for doctors, clinical researchers, and therapists is to understand and predict optimal doses of psychedelic inspired medicines for patients.
Through its clinical research, Liechti Lab has identified novel ways to predict and also optimize the amount of a psychedelic dose and dosing regimen for therapy. In order to assemble a patient’s personalized dosing regimen and therapy session, MindMed and Liechti Lab’s analytics method aggregates multiple data and criteria of patients in a pre-dose screening and analysis process. MindMed intends to apply this personalized medicine approach to psychedelic assisted therapies for patients suffering from mental health and addiction issues.
MindMed Co-Founder and Co-CEO JR Rahn said, “One size never fits all. Healing through psychedelics is a deeply personal process and we believe the personalization of psychedelic therapies is pivotal to the future of this fast growing field of medicine. Through such analytics and dosing technologies we hope to give patients the best possible outcome from their therapy experiences.”
The University Hospital Basel, in collaboration with MindMed, has filed two separate patent applications that cover MDMA dose optimization and LSD dose response. MindMed has received the exclusive rights from the University Hospital Basel to commercialize the outcome of these patent applications on a global basis.
University Hospital Basel’s Dr Matthias Liechti and Co-Inventor of the technology said “The dosing optimization approach includes dosing based on solid dose-response data, simple adjustments based on gender and body weight, but also includes pharmacogenetic and personality predictors to optimize dosing to induces specific mental states. MindMed has provided the long needed resources to ensure our Lab’s inventions can be further developed and hopefully reach the market faster and safer than ever before.”
MindMed possesses the world’s leading collection of human safety data and pharmacokinetics for both MDMA and LSD based on clinical studies. MindMed previously acquired the world-wide exclusive license to this collection of human safety data and pharmacokinetics on both LSD and MDMA from the University Hospital Basel. This data set is based on over 10 years of scientific and clinical research at the Liechti Lab.
About Liechti Laboratory (University Hospital Basel)
Liechti Lab is based at the University Hospital Basel in Basel Switzerland. Founded in 1460, the University of Basel is the oldest university in Switzerland and has a history of success going back over 550 years. Liechti Lab’s research focus is on the pharmacology of psychoactive substances in vitro and in humans. The Laboratory investigates the pharmacokinetics-pharmacodynamics of MDMA, LSD, and amphetamines in humans including psychological tests, pharmacogenetics, and functional brain imaging.
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company’s has initiated or is initiating studies to evaluate potential treatments to help patients with ADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:BGHM. For more information: www.mindmed.co.
MindMed is has engaged Proactive Investors North America Inc. (“Proactive“) to provide ongoing editorial coverage and to record and publish video interviews with MindMed’s management team.
Psychedelic Finance Engagement
The company has engaged CIFC Capital Corp operating under the trade name Psychedelic Finance to generate digital content and social media posts about the company.
MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying word. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs (including those discussed in this press release), MindMed’s ability to manage its supply chain, net product sales of products marketed by MindMed and/or its collaborators (collectively, “MindMed’s Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of MindMed’s Products and product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of MindMed’s product candidates and new indications for MindMed’s Products; unforeseen safety issues resulting from the administration of MindMed’s Products and product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize MindMed’s Products and product candidates; ongoing regulatory obligations and oversight impacting MindMed’s Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of MindMed’s Products and product candidates and the impact of studies (whether conducted by MindMed or others and whether mandated or voluntary) on the commercial success of MindMed’s Products and product candidates; the availability and extent of reimbursement of MindMed’s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to MindMed’s Products and product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by MindMed. MindMed does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Tel: + (212) 254-4730